# EDGAR Filing Document

**Accession Number:** 0001450416
**File Stem:** 0001104659-23-004303
**Filing Date:** 2023-1
**Character Count:** 132916
**Document Hash:** 8b29316b66266376dbd71adc6a9d0425
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-004303.hdr.sgml**: 20230117

**ACCESSION NUMBER**: 0001104659-23-004303

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 87

**CONFORMED PERIOD OF REPORT**: 20221130

**FILED AS OF DATE**: 20230117

**DATE AS OF CHANGE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LexaGene Holdings Inc.
- **CENTRAL INDEX KEY:** 0001450416
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0228

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56456
- **FILM NUMBER:** 23532188

**BUSINESS ADDRESS:**
- **STREET 1:** 500 CUMMINGS CTR., SUITE 4550
- **CITY:** BEVERLY
- **STATE:** MA
- **ZIP:** 01915
- **BUSINESS PHONE:** 800-215-1824

**MAIL ADDRESS:**
- **STREET 1:** 500 CUMMINGS CTR., SUITE 4550
- **CITY:** BEVERLY
- **STATE:** MA
- **ZIP:** 01915

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STONESHIELD CAPITAL CORP.
- **DATE OF NAME CHANGE:** 20100729

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STONESHIELD CAPITAL CORP
- **DATE OF NAME CHANGE:** 20081119

?xml version='1.0' encoding='UTF-8'?

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended November 30, 2022

OR

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .

**COMMISSION FILE NUMBER: 000-56456**

![Graphic](lxxgf-20221130x10q003.jpg)

**LEXAGENE HOLDINGS INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **British Columbia**<br>(State or other jurisdiction of<br>incorporation or organization) | **None**<br>(I.R.S. Employer Identification No.)<br>**01915**<br>(Zip Code) |

---

**500 Cummings Center**

**Suite 4550**

**Beverly, Massachusetts**

(Address of principal executive offices)

**‎(800) 215-1824‎**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| N/A | N/A | N/A |

---

**Securities registered pursuant to section 12(g) of the Act:**

**Common stock, no par value**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes **☒** No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes **☒** No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated Filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ☒ | Smaller reporting company | **☒** |
|  |  | Emerging growth company | **☒** |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No **☒**

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. The number of shares outstanding of the registrant's Common Stock, no par value per share, was 140,641,855 on January 17, 2023.

------

[**Table of Contents**](#TOC)

**LexaGene Holdings, Inc.**

**Form 10-Q November 30, 2022**

**Table of Contents**

---

| | |
|:---|:---|
| [PART I – Financial Information](#PARTIFINANCIALINFORMATION_771240) | 3 |
| [Item 1. Financial Statements](#ITEM1FINANCIALSTATEMENTS_918451) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Balance Sheets](#CONSOLIDATEDBALANCESHEETS_766460) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Operations and Comprehensive Loss](#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Equity](#CONSOLIDATEDSTATEMENTSOFEQUITY_440404) | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Cash Flows](#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_769466) | 6 |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF) | 26 |
| [Item 3. Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur) | 34 |
| [Item 4. Controls and Procedures](#Item4ControlsandProcedures_14928) | 34 |
| [PART II – other information](#PARTIIOTHERINFORMATION_480253) | 34 |
| [Item 1. Legal Proceedings](#Item1LegalProceedings_132686) | 34 |
| [Item 1A. Risk Factors](#Item1ARiskFactors_312964) | 34 |
| [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities) | 35 |
| [Item 3. Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_113764) | 35 |
| [Item 4. Mine Safety Disclosures](#Item4MineSafetyDisclosures_600140) | 35 |
| [Item 5. Other Information](#Item5OtherInformation_762884) | 35 |
| [Item 6. Exhibits](#Item6Exhibits_35453) | 35 |
| [SIGNATURES](#SIGNATURES_170261) | 37 |

---

[**Table of Contents**](#TOC)

**PART I – FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**LEXAGENE HOLDINGS, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(expressed in US Dollars)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **November 30,** <br>**2022** | **February 28,** <br>**2022** |
| **ASSETS** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $464131 | $4722710 |
| &nbsp;&nbsp;Accounts receivable | 51643 | 14375 |
| &nbsp;&nbsp;Inventories | 1445094 | 1396223 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 334810 | 439831 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | $2295678 | $6573139 |
| Property and equipment, net | 250146 | 369449 |
| Right-of-use asset, net | 910287 | 1161956 |
| Intangible license, net | 33653 | 48191 |
| Other long-term assets |  | 48087 |
| Total assets | $3489764 | $8200822 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;Accounts payable | $272170 | $219239 |
| &nbsp;&nbsp;Accrued and other current liabilities | 187171 | 352175 |
| &nbsp;&nbsp;Lease obligations - current | 350550 | 325271 |
| &nbsp;&nbsp;Convertible note payable, net of issuance costs | 845502 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | $1655393 | $896685 |
| Lease liabilities – non-current | 561160 | 838108 |
| Total Liabilities | $2216553 | $1734793 |
| Commitments |  |  |
| Shareholders' Equity |  |  |
| &nbsp;&nbsp;Common shares, $nil par value; unlimited shares authorized as of November 30, 2022 and February 28, 2022; 140,496,730 and 138,106,860 issued | 41376221 | 40384516 |
| &nbsp;&nbsp;Contributed surplus | 9900306 | 9833452 |
| &nbsp;&nbsp;Accumulated deficit | (50339236) | (44107572) |
| &nbsp;&nbsp;Accumulated other comprehensive income | 335920 | 355633 |
| Total shareholders' equity | 1273211 | 6466029 |
| Total liabilities and shareholders' equity | $3489764 | $8200822 |

---

*See Notes to Condensed Consolidated Financial Statements*

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(expressed in US Dollars)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Revenues | $42912 | $48309 | $117886 | $88934 |
| Cost of revenues |  |  |  |  |
| &nbsp;&nbsp;Net shipping costs | $4604 | $— | $22811 | $— |
| &nbsp;&nbsp;Cost of goods sold | 44338 | 49668 | 142149 | 88045 |
| &nbsp;&nbsp;Manufacturing costs | 140986 | 98903 | 427336 | 290143 |
|  | $189928 | $148571 | $592296 | $378188 |
| Gross loss | $(147016) | $(100262) | $(474410) | $(289254) |
| Selling, marketing and promotion expenses | $167316 | $546886 | $629848 | $1736549 |
| General and administrative expenses | 470999 | 544054 | 1424242 | 1607115 |
| Research and development expenses | 887336 | 1506024 | 3357090 | 4709756 |
|  | $1525651 | $2596964 | $5411180 | $8053420 |
| Operating loss | $(1672667) | $(2697226) | $(5885590) | $(8342674) |
| Other income |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange gain (loss) | $99 | $5546 | $99 | $32000 |
| &nbsp;&nbsp;Interest on convertible note payable | (5787) |  | (5787) |  |
| Net loss | $(1678355) | $(2691680) | $(5891278) | $(8310674) |
| Other comprehensive income (loss) |  |  |  |  |
| &nbsp;&nbsp;Foreign currency translation adjustments | (8637) | (4081) | (19713) | 152563 |
| Net loss and comprehensive loss | $(1686992) | $(2695761) | $(5910991) | $(8158111) |
| Net loss per common share, basic and diluted | $(0.01) | $(0.02) | $(0.04) | $(0.07) |
| Weighted average common shares used in computing net loss per common share, basic and diluted | 139008857 | 119230207 | 138617427 | 118971167 |

---

*See Notes to Condensed Consolidated Financial Statements*

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF EQUITY**

**(expressed in US Dollars)**

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Shares** | **Common Shares** | | | | |
|  | <br>**Shares** | <br>**Amount** | <br>**Contributed**<br> **Surplus** | <br>**Accumulated**<br>**Deficit** | <br>**Accumulated Other**<br> **Comprehensive**<br> **Income (Loss)** | <br>**Total Equity** |
| Balance – February 28, 2021 | 118566834 | $35839063 | $8098015 | $(33148882) | $191272 | $10979468 |
| &nbsp;&nbsp;Share-based payment of stock options |  |  | 163047 |  |  | 163047 |
| &nbsp;&nbsp;Share-based payment of restricted share units |  |  | 220970 |  |  | 220970 |
| &nbsp;&nbsp;Restricted share units vested | 268438 | 170000 | (170000) |  |  |  |
| &nbsp;&nbsp;Warrants exercised | 41200 | 28490 | (4302) |  |  | 24188 |
| &nbsp;&nbsp;Comprehensive income (loss) for the period |  |  |  | (2802895) | 336925 | (2465970) |
| Balance –May 31, 2021 | 118876472 | $36037553 | $8307730 | $(35951777) | $528197 | $8921703 |
| &nbsp;&nbsp;Share-based payment of stock options |  | $— | $144792 | $— | $— | $144792 |
| &nbsp;&nbsp;Share-based payment of restricted share units |  |  | 231516 |  |  | 231516 |
| &nbsp;&nbsp;Restricted share units vested | 180375 | 140904 | (140904) |  |  |  |
| &nbsp;&nbsp;Options exercised | 63750 | 92634 | (64862) |  |  | 27772 |
| &nbsp;&nbsp;Comprehensive income (loss) for the period |  |  |  | (2816099) | (180281) | (2996380) |
| Balance - August 31, 2021 | 119120597 | $36271091 | $8478272 | $(38767876) | $347916 | $6329403 |
| &nbsp;&nbsp;Share-based payment of stock options  |  | $— | $73082 | $— | $— | $73082 |
| &nbsp;&nbsp;Share-based payment of restricted share units  |  |  | 155822 |  |  | 155822 |
| &nbsp;&nbsp;Restricted share units vested | 223263 | 124700 | (124700) |  |  |  |
| &nbsp;&nbsp;Comprehensive income (loss) for the period  |  |  |  | (2691680) | (4081) | (2695761) |
| Balance – November 30, 2021 | 119343860 | $36395791 | $8582476 | $(41459556) | $343835 | $3862546 |
| Balance – February 28, 2022 | 138106860 | $40384516 | $9833452 | $(44107572) | $355633 | $6466029 |
| &nbsp;&nbsp;Restricted share units vested | 240513 | 125716 | (125716) |  |  |  |
| &nbsp;&nbsp;Share-based payment of stock options |  |  | 48384 |  |  | 48384 |
| &nbsp;&nbsp;Share-based payment of restricted share units |  |  | 119978 |  |  | 119978 |
| &nbsp;&nbsp;Comprehensive income (loss) for the period |  |  |  | (2135797) | (349) | (2136146) |
| Balance – May 31, 2022 | 138347373 | $40510232 | $9876098 | $(46243369) | $355284 | $4498245 |
| &nbsp;&nbsp;Restricted share units vested  | 383000 | $225878 | $(225878) | $— | $— | $— |
| &nbsp;&nbsp;Share issuance costs refund |  | 4836 |  |  |  | 4836 |
| &nbsp;&nbsp;Share-based payment of stock options  |  |  | 35075 |  |  | 35075 |
| &nbsp;&nbsp;Share-based payment of restricted share units  |  |  | 108072 |  |  | 108072 |
| &nbsp;&nbsp;Comprehensive income (loss) for the period  |  |  |  | (2077136) | (10727) | (2087853) |
| Balance – August 31, 2022 | 138730373 | $40740946 | $9793367 | $(48320495) | $344557 | $2558375 |
| &nbsp;&nbsp;Restricted share units vested  | 230088 | $147607 | $(147607) | $— | $— | $— |
| &nbsp;&nbsp;Share-based payment of stock options  |  |  | 33133 |  |  | 33133 |
| &nbsp;&nbsp;Share-based payment of restricted share units  |  |  | 105400 |  |  | 105400 |
| &nbsp;&nbsp;Warrant modification |  |  | 340385 | (340385) |  |  |
| &nbsp;&nbsp;Warrants exercised | 1536269 | 487668 | (224372) |  |  | 263296 |
| &nbsp;&nbsp;Comprehensive income (loss) for the period  |  |  |  | (1678355) | (8637) | (1686992) |
| Balance – November 30, 2022 | 140496730 | $41376221 | $9900306 | $(50339236) | $335920 | $1273211 |

---

*See Notes to Condensed Consolidated Financial Statements*

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(expressed in US Dollars)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** |
|  | **2022** | **2021** |
| **Cash flows from (used in) operating activities:** |  |  |
| Net loss | $(5891278) | $(8317324) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;Depreciation of intangible license | 12084 | 9673 |
| &nbsp;&nbsp;Depreciation of property and equipment | 119303 | 123817 |
| &nbsp;&nbsp;Depreciation of right-of-use asset | 251669 | 239420 |
| &nbsp;&nbsp;Interest on right-of-use asset | 39408 | 51657 |
| &nbsp;&nbsp;Interest on convertible note payable | 5787 |  |
| &nbsp;&nbsp;Share-based payments | 450042 | 990712 |
| &nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | (37268) | 5168 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | (48871) | (332390) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 105021 | (120325) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term asset | 48087 | (87387) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | (117855) | (372589) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | $(5063871) | $(7809568) |
| **Cash flows from investing activities:** |  |  |
| Purchases of property and equipment |  | (17860) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | $— | $(17860) |
| **Cash flows from financing activities** |  |  |
| Proceeds from warrant exercises, net of costs | 263296 | 24188 |
| Proceeds from stock option exercises, net of costs |  | 27772 |
| Refund of share issuance costs | 4836 |  |
| Proceeds from convertible note, net of issuance costs | 832436 |  |
| Principal payments on lease liability | (291077) | (291077) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | $809491 | $(239117) |
| Net decrease in cash | (4254380) | (8066545) |
| Cash - beginning | 4722710 | 9624259 |
| Effects of foreign exchange | (4199) | 157726 |
| Cash - ending | $464131 | $1715440 |

---

*See Notes to Condensed Consolidated Financial Statements*

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

1. DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS

#### Description of Business
LexaGene Holdings Inc. together with its subsidiaries, (collectively the "Company" or "LexaGene") was incorporated on April 26, 2007, under the laws of the province of British Columbia, Canada. The head office and the principal address is located at 500 Cummings Ctr., Suite 4550, Beverly, Massachusetts, USA, 01915. The records office of the Company is located at 1055 West Georgia Street, Suite 1500, Vancouver, British Columbia, Canada, V6E 4N7. The Company's common shares are publicly listed on the TSX Venture Exchange under the trading symbol "LXG" and quoted on the OTCQB under the symbol "LXXGF".

The principal business of the Company is to research, develop and commercialize automated genetic analyzer devices in veterinary, clinical and life science industries.

#### Liquidity and Going Concern
At November 30, 2022, the Company had cash of $464,131, an accumulated deficit of $(50,339,236), and has experienced cash outflows from operating activities over the past years. The Company's operations are dependent on obtaining additional financing to further develop its genetic analyzer, the MiQLab® System, and generating cash flow from operations in the future.

Management's plans to meet the Company's current and future obligations are to raise capital in equity and private debt markets, private placements, rely on the financial support of its shareholders and related parties as well as to further expand commercial sales of the MiQLab System. There can be no assurance that the Company will be successful in raising that additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditures.

The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company's products, development and market acceptance of the Company's product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.

The COVID-19 pandemic has impacted and may continue to impact operations. The Company has established protocols for continued manufacturing, distribution and servicing of its products with safe social distancing and personal protective equipment measures and for remote work for certain employees not essential to on-site operations. To date, these measures have been mostly successful but may not continue to function should the pandemic escalate and impact personnel. In 2021, the Company's veterinary customers restricted the sales team's access to their facilities and as a result, the Company had significantly reduced its sales and marketing staffing levels in an effort to reduce expenses. Although the Company did not see any material impact to accounts receivable during the period ended November 30, 2022, the Company's exposure may increase if its customers continue to be adversely affected by the COVID-19 pandemic and variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. The ability of the Company's shipping carriers to deliver products to customers may be disrupted. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and, in some cases, have alternate sources of critical materials including personal protective equipment should the supply chains become disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict.

The Company believes that its cash of $464,131 as of November 30, 2022 will not be sufficient to fund its current operating plan at least one year from issuance of these condensed financial statements unless additional funds are raised. Certain elements of our operating plan cannot be considered probable.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of issuance of these condensed consolidated financial statements.

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

#### Emerging Growth Company Status
The Company is an emerging growth company ("EGC"), as defined in Section 2(a)(19) of the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). Under section 107(b) of the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), EGCs can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the condensed consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board ("FASB") standards' effective dates. The Company can elect to early adopt, if permitted by the accounting standard. The Company may take advantage of this accommodation up until the last day of the fiscal year following the fifth anniversary of the date on which it first sells common equity securities pursuant to a registration statement under the U.S. Securities Act, or such earlier time that it is no longer an EGC.

#### Smaller Reporting Company Status
The Company is a "smaller reporting company" as defined in Exchange Act Rule 12b-2. As a result, the Company is eligible to take advantage of certain reduced disclosure and other requirements that are otherwise applicable to public companies including, but not limited to, not being subject to the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002. The Company will remain a smaller reporting company until the last day of the fiscal year in which (1) the aggregate worldwide market value of its common shares held by non-affiliates equaled or exceeded $250 million as of the prior June 30th, or (2) its annual revenues equaled or exceeded $100 million during such completed fiscal year and the aggregate worldwide market value of its common shares held by non-affiliates equaled or exceeded $700 million as of the prior June 30th.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

#### Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles of the United States ("U.S. GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") for interim financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board.

The accompanying interim condensed consolidated financial statements as of November 30, 2022, and for the three and nine months ended November 30, 2022 and 2021, and information contained within the notes to these condensed consolidated financial statements, are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company's audited annual consolidated financial statements and in management's opinion contain all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company's financial position as of November 30, 2022, results of operations for the three and nine months ended November 30, 2022 and 2021, statement of stockholders' equity for the three and nine months ended November 30, 2022 and 2021 and its cash flows for the nine months ended November 31, 2022 and 2021.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

These interim condensed consolidated financial statements should be read in conjunction with the Company's annual audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10 for the year ended February 28, 2022. The results for the nine months ended November 30, 2022, are not necessarily indicative of the results expected for the full fiscal year or any interim period.

The condensed consolidated financial statements for the periods ended November 30, 2022 and 2021, include the accounts of the Company, the Company's wholly-owned Canadian subsidiary Bionomics Diagnostics Inc. ("BDI") and the Company's wholly-owned US subsidiary LexaGene, Inc. All inter-company transactions and balances have been eliminated.

The consolidated financial statements include the financial statements of LexaGene Holdings Inc. and its subsidiaries listed as follows:

---

| | | | |
|:---|:---|:---|:---|
| | | **% Ownership Interest** | **% Ownership Interest** |
| <br>**Name** | <br>**Country of Incorporation** | **2022** | **2021** |
| Bionomics Diagnostics Inc. | Canada | 100% | 100% |
| LexaGene, Inc. | United States of America | 100% | 100% |

---

#### Foreign Currency
These condensed consolidated financial statements are expressed in US dollars ("USD") and have been prepared on a historical cost basis except for certain financial instruments that have been measured at fair value. The functional currency of the Company and its Canadian subsidiary is the Canadian dollar ("CAD"), and the USD for the Company's US subsidiary.

The Company's presentation currency is the USD which aligns the Company's presentation currency with the functional currency of its operations in the United States. Under this method, the Canadian entities are translated to USD.

Translation gains and losses resulting from the consolidation of operations in Canada are recognized in other comprehensive loss in the consolidated statements of comprehensive loss, and in accumulated other comprehensive loss as a separate component of shareholders' equity on the consolidated statement of changes in equity.

Foreign exchange rates used for currency translation in these consolidated financial statements include:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period end dates** |  | **USD to CAD** |  | **CAD to USD** |
| November 30, 2022 |  | 1.3508 |  | 0.7403 |
| February 28, 2022 |  | 1.2698 |  | 0.7875 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period averages** |  | **USD to CAD** |  | **CAD to USD**  |
| Period ended November 30, 2022 |  | 1.3023 |  | 0.7685 |
| Period ended November 30, 2021 |  | 1.2470 |  | 0.8021 |

---

#### Use of Estimates
The preparation of these condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures. We evaluate our estimates on an on-going basis, including those related to accounts receivable; inventory valuation; revenue recognition, share-based compensation. Our estimates are based on historical experience and on other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from these estimates. Significant judgments relate to the recognition of deferred income taxes, treatment of development costs, recoverability of the carrying value of intangible assets, and going concern.

Management believes that there have been no significant changes during the nine months ended November 30, 2022 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Form 10 for the fiscal year ended February 28, 2022.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

#### Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company's chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, launching commercially its diagnostic products.

#### Geographic Information
All sales to date were made in the United States of America.

#### Cash
The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. The Company maintains its cash and cash equivalents in accounts that, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.

#### Accounts Receivable
The Company's accounts receivable consists of amounts due from product sales to commercial customers and goods and services tax ("GST") receivable from the government of Canada. At each reporting period, management reviews historical loss information, characteristics of our customers, our credit practices and the economic conditions, along with all outstanding balances to determine if the facts and circumstances indicate the need for a credit loss allowance. Receivables are written off against these allowances in the period they are determined to be uncollectible. The Company does not require collateral and did not have an allowance for doubtful accounts as of November 30, 2022 and February 28, 2022.

#### Inventories
Raw materials, work in process, and finished goods inventories are stated at the lower of cost and net realizable value, with cost being determined using a first-in-first-out costing ("FIFO") method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. At the end of each reporting period, management reviews inventory and determines whether a write-down is required based on the assumptions about future demand of the Company's products, estimated future sales, remaining shelf life and market conditions.

#### Fair Value Measurements
The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, *Fair Value Measurements and Disclosures* ("ASC 820"), establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.

Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:

Level 1 — Quoted unadjusted prices for identical instruments in active markets.

Level 2 — Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

Level 3 — Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions developed by the Company.

The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

For certain financial instruments, including cash, accounts receivable, accounts payable and convertible note, the carrying amounts approximate their fair values as of November 30, 2022 and February 28, 2022 because of their short-term nature.

The Company recognizes a loss allowance for expected credit losses on its financial assets when necessary. The amount of expected credit losses is updated at each reporting period to reflect changes in credit risk since initial recognition of the respective financial instruments. The Company did not recognize impairment losses during the periods ended November 30, 2022 and 2021.

The Company has no hedging arrangements and does not apply hedge accounting.

#### Property and Equipment
Property and equipment are initially recognized at acquisition cost, including any costs directly attributable to bringing the assets to the location and condition necessary for it to be capable of operating in the manner intended by the Company. Property and equipment are subsequently measured using the cost model, cost less amortization and impairment. The costs of additions and improvements are capitalized, and the costs of maintenance and repairs are expensed as incurred.

Amortization is recognized on a straight-line basis to amortize the cost over the estimated useful life of the property and equipment as follows:

---

| | | |
|:---|:---|:---|
| Computer equipment |  | 3 years; |
| Furniture and fixtures |  | 7 years; |
| Lab equipment |  | 5 to 7 years; |
| Laboratory and leasehold improvements |  | Remaining lease term. |

---

Significant improvements that extend the useful life of an asset are capitalized. Repairs and maintenance which do not extend the useful lives of assets are expensed as incurred. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gains or losses are recognized.

#### Impairment of Non-Financial Assets
The Company reviews intangible assets with indefinite useful lives for impairment at least annually and reviews all intangible assets for impairment whenever events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. Long-lived assets, such as property and equipment and intangible assets subject to depreciation and amortization, as well as indefinite lived intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable or that the useful life is shorter than the Company had originally estimated. Recoverability of these assets is measured by comparison of the carrying amount of each asset or asset group to the future undiscounted cash flows the asset or asset group is expected to generate over their remaining lives. If the asset or asset group is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset or asset group. If the useful life is shorter than originally estimated, the Company amortizes the remaining carrying value over the new shorter useful life. There were no impairment losses recognized for the periods ended November 30, 2022 and 2021.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

#### Leases
At the inception of a contract, LexaGene assesses whether the arrangement may contain a lease. The Company recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases). Right-of-use assets are depreciated over the lease term from the commencement date of the lease over the shorter of the useful life of the right-of-use asset or the end of the lease term.

The lease liability is initially measured at the present value of the future lease payments from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that in management's assessment is reasonably certain to be exercised by the Company. The lease liability is measured at amortized cost using effective interest method.

The Company remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or a modification that is not accounted for as a separate lease. As changes in LexaGene's lease payments are related to changes in the consumer price index, the lease liability is not remeasured due to the changes in lease payments unless the liability is remeasured for another reason. The excess of current lease payments over the lease payments at commencement date is recognized as rent expense.

#### Revenue Recognition
Revenues are recognized in accordance with ASC 606, *Revenue from Contracts with Customers* using the five-step model described below:

● Identify contract with customer;

● Identify performance obligations;

● Determine transaction price;

● Allocate transaction price to performance obligations;

● Recognize revenue when performance obligations are satisfied.

Performance obligations are considered satisfied when control of the products has transferred to the customer, and the customer has full discretion over the use of the products, generally upon delivery. Delivery occurs at a point in time when the products have been shipped to the specific location requested by the customer, the customer takes control of the goods at a designated warehouse, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, the acceptance provisions have lapsed, or the Company has objective evidence that all criteria for acceptance have been satisfied. As at the end of the reporting period, there are no unfulfilled performance obligations.

The Company elected to use a practical expedient to expense sales commissions as they are incurred because the amortization period would have been less than one year. The Company's products are sold without any subsequent pricing adjustments or contingencies related to occurrence or non-occurrence of future events. Accordingly, there has been no variable consideration assessment. LexaGene's sales require an advance payment or payment within 30 to 60 days, which is why there is no financing component associated with sales.

Accounts receivable are recognized when the goods are controlled by the customer at the point in time that the consideration is unconditional, and only the passage of time is required before payment is due. Any advance payments are recorded as a liability called deferred revenue.

Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company's direct sales force in the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers.

Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is generally recognized upon shipment.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

*Disaggregation of Revenue*

The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates total revenue by major source:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended November,** | **Three Months Ended November,** | **Nine Months Ended November,** | **Nine Months Ended November,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Product revenue |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Instruments and consumables | $42912 | $48309 | $117886 | $88934 |
| Total revenue | $42912 | $48309 | $117886 | $88934 |

---

Revenue earned during the periods ended November 30, 2022 and 2021 was derived from the customers located in the United States.

*Warranty Obligations*

The Company provides for the estimated cost of standard product warranties for a period of twelve months from installation date. Due to limited sales history, warranty obligation is based on the Company's best estimate of potential repair costs and is recognized at the time of revenue recognition. Accrual for warranty obligations is included in accrued and other liabilities in the consolidated balance sheet. Extended warranty agreements are considered service contracts.

*Contract-Related Balances*

The Company has current contract liabilities (deferred revenue) in the amount of $282 as of November 30, 2022 (February 28, 2022 - $23,560). Amount recognized in revenue during the nine months period ended November 30, 2022 in connection with the contract liabilities was $23,278.

#### Research and Development Costs
Costs incurred in the research and development of the Company's product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, costs associated with the enhancements of developed products and include salaries and benefits, stock compensation, research-related facility and overhead costs, laboratory supplies, equipment and contract services.

#### Stock-Based Compensation and Value of Warrants
The Company issues stock-based awards to employees, generally in the form of stock options and restricted stock units ("RSUs"). The Company accounts for stock-based awards in accordance with FASB ASC Topic 718, *Compensation-Stock Compensation*, or ASC 718. ASC 718 requires all stock-based payments to employees, including grants of employee stock options, restricted stock units, and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The fair value of awards is amortized on a straight-line basis over the requisite service period of the awards, which generally is the same as the vesting period. The number of RSUs and options expected to vest is viewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest. Forfeitures are recognized as they occur.

The Company estimates the fair value of the stock-based awards to employees using the Black-Scholes-Merton option pricing model, which requires the input of highly subjective assumptions, including (a) the expected volatility of the stock, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividends. The Company estimates expected volatility based on the historical volatility of the stock using the daily closing prices during the equivalent period of the calculated expected term of its stock-based awards. Expected life is estimated on the actual exercise and expiries of options. Risk-free rate is based on the Bank of Canada interest rate with a term that represents expected life of the options at grant date. The Company has not paid, and does not anticipate paying, cash dividends on shares of common stock; therefore, the expected dividend yield is assumed to be zero.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

These assumptions used to determine stock compensation expense represent the Company's best estimates, but the estimates involve inherent uncertainties and the application of judgment. As a result, if factors change and the Company uses significantly different assumptions or estimates, stock-based compensation expense could be materially different. Refer to Note 10 for further details on the Company's share-based compensation plan.

The fair value of warrants issued as units in private placements is estimated using the relative fair value method whereby the value of the warrants issued is estimated using the Black-Scholes Pricing Model and the value of the shares issued is based on the market price at the time of issuance. Total private placement proceeds are then allocated to shares and warrants based on their relative fair values.

#### Income Taxes
The Company applies ASC 740, *Income Taxes* ("ASC 740") in accounting for uncertainty in income taxes. The Company does not have any material uncertain tax positions for which reserves would be required. The Company will recognize interest and penalties related to uncertain tax positions, if any, in income tax expense.

Income tax expense comprises of current and deferred tax. Current tax and deferred tax are recognized in profit or loss, except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive income (loss).

Current income taxes are recognized for the estimated income taxes payable or receivable on taxable income or loss for the current period and any adjustment to income taxes payable in respect of previous periods.

Current tax expense is the expected tax payable on the taxable income for the period using tax rates enacted at year-end, adjusted for amendments to tax payable with regard to previous years. Deferred tax assets and liabilities are recognized for deferred tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled.

A deferred tax asset is recognized to the extent that is probable that future taxable profits will be available against which the asset can be utilized. The Company realizes deferred income tax assets to the extent that it is more likely than not to be realized and provides a valuation allowance against any excess that may not be realized.

#### Basic and Diluted Net Loss per Share
Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. The Company uses the treasury stock method to compute the dilutive effect of options, warrants and similar instruments. Under this method the dilutive effect on earnings per share is calculated presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be antidilutive. Shares held in escrow, other than where their release is subject to the passage of time, are not included in the calculation of the weighted average number of common shares outstanding.

As the Company incurred losses since inception, basic and diluted loss per share presented are the same. Securities that may potentially dilute earnings per share in the future that were not included in the calculation are as follows as of November 30, 2022:

---

| | |
|:---|:---|
| Warrants | 26352247 |
| Stock Options<sup>1</sup> | 3490750 |
| Restricted Share Units | 2222027 |
| Total | 32065024 |

---

<sup>1</sup> Vested –1,654,600

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

These securities were not included in the calculation as they are anti-dilutive.

#### Recent Accounting Standards
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

Effective September 1, 2022, the Company elected to adopt ASU 2020-06, *Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40)* using the full retrospective method. The ASU simplifies accounting for convertible instruments by eliminating the cash conversion and the beneficial conversion feature. As a result of the adoption, the Company recognized the total value of the convertible note payable as a liability and did not recognize a discount related to the beneficial conversion feature. The adoption of the standard did not have an impact on prior periods presented in the consolidated financial statements.

In May 2021, the FASB issued ASU No. 2021-04, *Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40) Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options ("ASU 2021-04")*. The adoption of this ASU did not have a significant impact on our condensed consolidated financial statements.

In July 2021, the FASB issued ASU 2021-05—*Leases* (Topic 842): Lessors—*Certain Leases with Variable Lease Payments*. ASU is intended to improve lessor accounting for certain leases with variable payments. The adoption of this ASU did not have a significant impact on our condensed consolidated financial statements.

In November 2021, the FASB issued ASU No. 2021-10, *Government Assistance*, to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. The adoption of this ASU did not have a significant impact on our condensed consolidated financial statements.

*Accounting Standards Issued, To Be Adopted*

In October 2021, the FASB issued ASU 2021-08, *Accounting for Contract Assets and Contract Liabilities from Contracts with Customers*. ASU 2021-08 requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities (deferred revenue) from acquired contracts using the revenue recognition guidance in *Topic 606*. Under this approach, the acquirer applies the revenue model as if it had originated the contracts as compared to the previous approach of measuring contract assets and contract liabilities at fair value. This ASU is effective for fiscal years beginning after December 15, 2022. The adoption of this standard is not expected to have a material impact on the Company's financial statements.

In June 2022, the FASB issued ASU 2022-03, *Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.* ASU 2022-03 clarifies the guidance in Topic 820, *Fair Value Measurement*, contractual sale restrictions of equity securities by differentiating between two types of restrictions:

● Restrictions being a characteristic of the equity security (e.g. unregistered securities), which should be included in the calculation of the fair value of the security

● Restrictions being a characteristic of the holder of the security, which should not be included in the calculation of the fair value of the security.

The amendments also clarify that an entity cannot recognize a contractual sale restriction as a separate unit of account (i.e. as a contra-asset or separate liability); and require new disclosures for all entities with equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and early adoption is permitted. Management is still assessing the impact of the adoption of the standard on the Company's financial statements.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

3. ACCOUNTS RECEIVABLE

Accounts receivable are recognized when the goods are controlled by the customer at the point in time that the consideration is unconditional, and only the passage of time is required before payment is due. Any advance payments are recorded as a liability called deferred revenue.

Accounts receivable consists of the following:

---

| | | |
|:---|:---|:---|
|  | **November 30, 2022** | **February 28, 2022** |
| Accounts receivable | $51643 | $14375 |
| Less: loss allowance |  |  |
| Total accounts receivable, net | $51643 | $14375 |

---

The Company assesses, on a forward-looking basis, the expected credit losses associated with its assets carried at fair value. The impairment methodology applied depends on whether there has been a significant increase in credit risk. For trade receivables only, the Company applies the approach permitted by ASU 2016-13, which requires expected lifetime losses to be recognized from initial recognition of the receivables. The Company recognizes a loss allowance for expected credit losses on its financial assets when necessary. The amount of expected credit losses is updated at each reporting period to reflect changes in credit risk since initial recognition of the respective financial instruments. The Company did not recognize impairment losses during the period ended November 30, 2022 or the year ended February 28, 2022. Trade receivables are non-interest bearing and are on 30- to 60-day terms.

The ageing analysis of trade receivables is as follows:

---

| | | |
|:---|:---|:---|
|  | **November 30, 2022** | **February 28, 2022** |
| **Amounts Past Due:** |  |  |
| Current | $43806 | $7368 |
| Past due 1-30 days |  |  |
| Past due 31-60 days | 1250 |  |
| Past due 61-120 days |  | 2965 |
| Past due more than 120 days | 6587 | 4042 |
| Total accounts receivable | $51643 | $14375 |

---

Amounts in accounts receivable are based on customer sales, and goods and service tax refunds due to the Company from the Canadian Revenue Agency. As of November 30, 2022, the amount receivable of $12,146 was in relation to GST refunds. Amounts due for more than 120 days relate to GST receivable from the Canada Revenue Agency. These amounts were collected subsequent to November 30, 2022. As of February 28, 2022, $14,375 was in relation to GST refunds.

4. INVENTORIES

Inventories consist of the following:

---

| | | |
|:---|:---|:---|
|  | **November 30, 2022** | **February 28, 2022** |
| Raw materials | $735808 | $724584 |
| Work-in-process | 542833 | 584243 |
| Finished goods | 166453 | 87396 |
| Total inventories | $1445094 | $1396223 |

---

Cost comprises of direct materials and delivery costs, direct labor, import duties and other taxes, an appropriate proportion of variable and fixed overhead expenditure based on normal operating capacity. Costs of purchased inventory are determined after deducting rebates and discounts received or receivable. The costs are reflected in Cost of goods sold in the Statement of operations and comprehensive loss as cost of inventory sold at the time of sale of the related inventories.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

5. INTANGIBLE LICENSE

On February 4, 2015, the Company and Lawrence Livermore National Security ("LLNS") entered into a license agreement, whereby the Company has exclusive right to develop, manufacture and sell pathogen detection devices designed to identify bacteria and viruses that can cause disease with applications in both food safety and healthcare.

As consideration for the license agreement, the Company paid a non-refundable License Issue Fee of $60,000.

In addition, the Company is required to pay to LLNS a non-refundable US Maintenance Patent Fee of $45,000 as follows:

● $15,000 (paid) on or before February 29, 2016;

● $15,000 (paid) on or before February 28, 2019; and

● $15,000 to be paid on or before February 28, 2023.

In the event that the Company grants sublicenses, the Company will collect an issue fee equal to or greater than the License Issue Fee mentioned above. The Company will pay to LLNS 50% of any License Issue Fee from sublicensing.

In addition, the Company will pay LLNS a minimum annual royalty. This minimum annual royalty will be credited against the earned royalty of 3% due on all net sales. The minimum annual royalty is due as follows:

● $5,000 (paid) on or before February 28, 2017;

● $10,000 (paid) on or before February 28, 2018;

● $10,000 (paid) on or before February 28, 2019;

● $25,000 on or before February 28, 2021 and each year thereafter (paid according to the schedule).

The license agreement will remain in effect until the expiration or abandonment of the last of the patent rights. Patent US 8,298,763 B2 expires on February 27, 2028 and patent US 8,828,716 B2 expires on February 28, 2028.

A continuity schedule of changes in carrying value of the intangible license:

---

| | |
|:---|:---|
| **Cost** |  |
| Balance, February 28, 2022 | $115420 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign exchange differences | (6918) |
| Balance November 30, 2022 | $108502 |
| **Accumulated amortization** |  |
| Balance, February 28, 2022 | $67229 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions | 12084 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign exchange differences | (4464) |
| Balance November 30, 2022 | $74849 |
| **Carrying values** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;February 28, 2022 | $48191 |
| &nbsp;&nbsp;&nbsp;&nbsp;November 30, 2022 | $33653 |

---

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

**6. PROPERTY AND EQUIPMENT**

As of November 30, 2022, the continuity schedule of changes in the net book value of property and equipment is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| <br>**Cost** | **Computer** <br>**Equipment** | **Lab** <br>**Equipment** | **Furniture &** <br>**Fixtures** | **Leasehold** <br>**Improvements** | <br>**Total** |
| Balance, February 28, 2022 | $15577 | $448936 | $88062 | $419443 | $972018 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions |  |  |  |  |  |
| Balance, November 30, 2022 | $15577 | $448936 | $88062 | $419443 | $972018 |
| **Accumulated amortization** |  |  |  |  |  |
| Balance, February 28, 2022 | $14729 | $302835 | $56898 | $228107 | $602569 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions | 848 | 61378 | 11058 | 46019 | 119303 |
| Balance, November 30, 2022 | $15577 | $364213 | $67956 | $274126 | $721872 |
| **Carrying values** |  |  |  |  |  |
| February 28, 2022 |  |  |  |  | $369449 |
| November 30, 2022 |  |  |  |  | $250146 |

---

7. RIGHT-OF-USE ASSET AND LEASE LIABILITY

As of November 30, 2022, the balance of the lease liability is as follows:

---

| | |
|:---|:---|
|  | **Carrying Value** |
| Balance February 28, 2022 | $1163379 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 39408 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease payments | (291077) |
| Balance, November 30, 2022 | $911710 |
| Current portion of the lease liability | (350550) |
| Non - current portion of the lease liability, November 30, 2022 | $561160 |

---

As of November 30, 2022, the balance of the right-of-use asset is as follows:

---

| | |
|:---|:---|
|  | **Carrying Value** |
| Balance, February 28, 2022 | $1161956 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | (251669) |
| August, November 30, 2022 | $910287 |

---

The property lease expires on May 30, 2025 and the lease payments were discounted with a 5% interest rate**.** Lease payments are variable, tied to the consumer price index.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

Maturities of operating lease liabilities are as follows:

---

| | |
|:---|:---|
|  | **November 30, 2022** |
| 2023 | $97026 |
| 2024 | 388103 |
| 2025 | 388103 |
| 2026 | 97026 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease payments | 970258 |
| Less imputed interest | (58548) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease liability (current and long-term) | $911710 |

---

8. CREDIT AGREEMENTS

#### Convertible Note Payable
On November 1, 2022, the Company issued a secured convertible note payable (the "Note") to Meridian LGH Holdings 2, LLC, (the "Lender") an affiliate of an insider of the Company, in the aggregate principal amount of up to $1,600,000. The Note matures on March 1, 2023 and has an interest rate of 12%, unless an event of default has occurred and is continuing, at which time at the election of the Meridian LGH Holdings, interest would accrue at a rate equal to the lesser of 16% per annum or the maximum rate permitted under applicable law. The Note contains customary events of default, which accelerate the maturity date of the Note. The Note also contains an accelerated maturity clause if the Company obtains equity financing of not less than $5,000,000, completes a merger, an amalgamation or a sale of all or substantially all assets of the Company.

The Note is convertible in full or in part at any time at the discretion of Meridian LGH Holdings 2, LLC, into common shares of the Company at the rate of $0.17 (CAD$0.23) per share. Accrued interest is converted at the last closing price of the Company's Shares on the TSX-V on the day prior to issuing a news release announcing the conversion. The Note is collateralized by the assets of the Company and is guaranteed by the subsidiaries of the Company.

The Company accounted for the Note in accordance with ASC 815, *Derivatives and Hedging* ("ASC 815"). After assessment of the Note, no embedded features requiring bifurcation from the debt host contract were identified.

As of November 30, 2022, the Company received a total of $900,000 from the Lender. The Company paid $67,564 in issuance costs related to the debenture, which were recorded as a reduction of the balance of the Note. Debt issuance costs are being amortized using the straight-line method over the term of the Note, which matures on March 1, 2023.

As of November 30, 2022, the net carrying value of the Note is as follows:

---

| | |
|:---|:---|
|  | **November 30, 2022** |
| Principal | $900000 |
| Unamortized debt issuance costs | (54498) |
| &nbsp;&nbsp;Convertible note payable, net | $845502 |

---

The Company recognized Interest expense recorded under the Note was $5,787 for the three and nine-month periods ended November 30, 2022. As of January 17, 2023, the Company was in compliance with the terms of the Note.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

9. EQUITY

As of November 30, 2022, the Company's share capital consists of issued and outstanding shares of Common Shares.

#### Common Shares
As of November 30, 2022, the Company was authorized to issue an unlimited number of common shares, which have no par value.

*Dividend Rights* – Holders of common shares are entitled to receive dividends out of the assets available for the payment of dividends at such times and in such amount and form as the Board of Directors may determine from time to time, on the following basis, and otherwise without preference or distinction between the common shares. The Company is permitted to pay dividends unless there are reasonable grounds for believing that the Company is insolvent or the payment of the dividend would render the Company insolvent.

*Voting Rights* – Holders of common shares shall be entitled to receive notice of and to attend and vote at all meetings of shareholders of the Company except a meeting at which only the holders of another class or series of shares is entitled to vote. Each common share shall entitle the holder thereof to one vote at each such meeting.

*Liquidation Rights* – Holders of common shares will be entitled to receive all of the Company's assets remaining after payment of all debts and other liabilities.

#### Share Offering Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in ASC 480, *Distinguishing Liabilities from Equity*, and ASC 815. The assessment considers whether the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Any change in fair value of the warrants is recognized in the Company's statements of operations.

In February 2022, the Company issued 18,500,000 units at a price of CAD$0.35 per unit for an aggregate purchase price of $4,995,000 (CAD$6,475,000). Each unit consists of one common share of the Company and one common share purchase warrant. Each warrant is exercisable into one common share of the Company at the price of CAD$0.45 (approximately $0.36) per share for a period of 36 months. The value of the warrants of $1,139,791 was calculated using Black- Scholes Model and relative fair value method using the following assumptions: annualized volatility – 80%; risk-free rate – 1.35%; expected life – 1.58 years; expected dividend rate – 0%.

On October 27, 2022, the Company modified 7,776,893 warrants by extending their term by one month and reducing their exercise price from CAD$0.75 to CAD$0.23. This resulted in an amount of $340,385 being recognized as an additional value related to the warrants. The value was calculated using the Black-Scholes Model with the following assumptions: annualized volatility – 278%; risk-free rate – 3.85%; expected life – 0.08 years; expected dividend rate – 0%.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

The following summarizes the number of warrants outstanding as of November 30, 2022:

---

| | | |
|:---|:---|:---|
|  | <br>**Number of Warrants** | **Weighted-Average Exercise Price per** <br>**Warrant, CAD$** |
| Outstanding as of February 28, 2022 | 34579760 | $0.66 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted |  | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercised | (1536269) | $0.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;Expired | (6691244) | $0.25 |
| Outstanding as of November 30, 2022 | 26352247 | $0.64 |

---

Details of warrants outstanding as of November 30, 2022, are as follows:

---

| | | |
|:---|:---|:---|
| **Number of**<br>**Warrants** | **Exercise Price**<br>**(CAD$)** | <br>**Expiry Date** |
| 7852247 | $1.10 | September 9, 2023 |
| 13115275 | $0.45 | February 7, 2025 |
| 5384725 | $0.45 | February 18, 2025 |
| 26352247 |  |  |

---

As of November 30, 2022, the weighted average remaining contractual life of warrants outstanding was 1.77 years (February 28, 2022 – 2.08 years) with a weighted average exercise price of $0.47 (CAD$0.64) (February 28, 2022 - $0.52 (CAD$0.66)).

10. SHARE-BASED COMPENSATION

#### Share Incentive Plans
*Omnibus incentive plan ("OIP")*

The Shareholders and Board previously approved the OIP on July 25, 2017. After Shareholder approvals, the OIP was amended on August 23, 2019, November 10, 2020 and on December 16, 2021. The Company increased the number of Common Shares reserved for the Company's OIP and increased the number of Common Shares reserved for the issuance as share incentive options. As of November 30, 2022, the amended OIP grants the Company 8,354,070 Common Shares reserved for stock options and 8,354,070 reserved for restricted share units.

*Stock options*

Stock options vest over a prescribed service period and are approved by the Board of Directors on an award-by-award basis. Options have a prescribed service period generally lasting up to ten years, with certain options vesting immediately upon issuance. Upon the exercise of any stock options, the Company issues shares to the award holder from the pool of authorized but unissued common shares.

On July 29, 2022, the Company granted 935,000 stock options to non-insider employees with an expiration date of July 29, 2027 and 150,000 stock options to an officer of the Company with an expiration date of July 29, 2032. Each Option is exercisable into one common share of the Company at a price of CAD$0.20 per Share. Employee options are exercisable for a period of five years and officer options are exercisable for ten years from the date of grant. The CAD$0.13 per share was at the close price of the Company's stock on the TSX Venture Exchange on July 28, 2022. The Options vest 10% on the grant date, and 15% every six months thereafter. The Chief Executive Officer, Chief Financial Officer and the board of directors were excluded from this grant.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

Details of the number of stock options outstanding for the period ended November 30, 2022 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Number of** <br>**Options** | <br>**Weighted-Average** <br>**Exercise Price per** <br>**Option, CAD$** | **Weighted-**<br>**Average** <br>**Remaining** <br>**Contract Term** <br>**(in years)** | <br>**Aggregate** <br>**Intrinsic Value** |
| Outstanding as of February 28, 2022 | 4266000 | $0.61 | 5.08 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 1085000 | $0.20 | 5.69 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercised |  | $— |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited (and expired) | (1860250) | $0.53 |  |  |
| Outstanding as of November 30, 2022 | 3490750 | $0.53 | 6.12 | $— |
| Exercisable /vested as of November 30, 2022 | 1654600 | $0.64 | 6.49 | $— |

---

The average share price during the nine months period ended November 30, 2022 was $0.13 (CAD$0.18) (2021 - $0.50 (CAD$0.62)).

As of November 30, 2022, the weighted average remaining contractual life of options outstanding was 6.12 years (February 28, 2022 – 5.08 years), with a weighted average exercise price of $0.39 (CAD$0.53) (February 28, 2022 - $0.48 CAD$0.61)). As of November 30, 2022, 1,654,600 stock options were exercisable (February 28, 2022 – 1,987,300).

The following table summarizes information on stock options outstanding as of November 30, 2022:

---

| | | | |
|:---|:---|:---|:---|
| **Options**<br>**Outstanding** | **Options**<br>**Exercisable** | **Exercise**<br>**Price, CAD$** | **Expiry**<br>**Date** |
| 17500 | 12250 | 0.82 | December 9, 2023 |
| 294000 | 123000 | 0.79 | December 10, 2024 |
| 306750 | 182550 | 0.49 | May 28, 2025 |
| 100000 | 100000 | 0.81 | September 17, 2025 |
| 183500 | 23750 | 0.285 | January 10, 2027 |
| 650000 |  | 0.20 | July 29, 2027 |
| 225000 | 168750 | 0.72 | February 19, 2030 |
| 100000 | 75000 | 0.63 | April 24, 2030 |
| 350000 | 350000 | 0.66 | September 17, 2030 |
| 324000 | 199800 | 0.66 | May 11, 2031 |
| 690000 | 379500 | 0.59 | May 28, 2031 |
| 100000 | 40000 | 0.66 | November 11, 2031 |
| 150000 |  | 0.20 | July 29, 2032 |
| 3490750 | 1654600 |  |  |

---

*Restricted share units*

The Company has issued time-based restricted share awards to certain employees as permitted under the OIP Plan. The restricted share units granted vest in accordance with the Board-approved vesting schedules with expiry dates less than or equal to three years. Upon vesting, one of the Company's common shares is issued for each restricted share awarded. The fair value of each restricted share award granted is equal to the market price of the Company's shares at the date of the grant. The total fair value of shares vested and total intrinsic value of the RSUs released during the nine-month period ended November 30, 2022 were $502,591 and $134,478 respectively.

On July 29, 2022, the Company granted 1,275,000 restricted share units to employees and 250,000 restricted share units to an officer of the Company with vesting dates of 10% on December 29, 2022, 15% on May 29, 2023, 15% on October 29, 2023, 15% on March 29, 2024, 15% on August 29, 2024, 15% on December 29, 2024 and 15% on February 28, 2025 and have an expiry date of February 28, 2025. The Chief Executive Officer, Chief Financial Officer and the board of directors were excluded from this grant.

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

Details of the number of restricted share awards outstanding under the OIP Plan is as follows:

---

| | | |
|:---|:---|:---|
|  | <br>**Number of Shares** | **Weighted-Average Grant** <br>**Date Value CAD$** |
| Outstanding as of February 28, 2022 | 2339928 | $0.62 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 1525000 | $0.14 |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (767300) | $0.30 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (875601) | $0.77 |
| Outstanding as of November 30, 2022 | 2222027 | $0.35 |

---

11. RESEARCH AND DEVELOPMENT EXPENSES

LexaGene's product research and development plan was divided into three phases: alpha prototype, beta prototype, and commercialization of its finished product the MiQLab System. On occasion, the Company engages various contractors to assist the Company in the development of its MiQLab System and other technologies.

*The significant components of research and development expense are as follows:*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Product development consulting expense | $— | $— | $40456 | $48630 |
| Depreciation of lab related equipment | 26251 | 28389 | 82523 | 87108 |
| Depreciation of the intangible license | 3890 | 4177 | 12084 | 9673 |
| Depreciation of right-of-use asset | 31011 | 29448 | 91884 | 87364 |
| Lab administration and supplies | 101100 | 141042 | 428564 | 395768 |
| Materials | 60232 | 327210 | 415735 | 999528 |
| Rent expense | 2821 | 754 | 7522 | 1508 |
| Travel | 482 | 5109 | 12282 | 17554 |
| Salaries | 630764 | 886232 | 2146302 | 2699286 |
| Share-based compensation | 30785 | 83663 | 119738 | 363337 |
| Total research and development expenses | $887336 | $1506024 | $3357090 | $4709756 |

---

12. GENERAL AND ADMINSTRATIVE EXPENSES

*The significant components of general and administrative expenses are as follows:*

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Office and administration | $12144 | $12565 | $31703 | $44037 |
| Depreciation of property and equipment | 12196 | 12382 | 36780 | 36708 |
| Depreciation of right-of-use asset | 53927 | 51356 | 159785 | 152056 |
| Consulting | 156 | 430 | 392 | 3119 |
| Promotional services | 8611 | 110776 | 25614 | 257040 |
| Professional fees | 189308 | 101743 | 591889 | 258194 |
| Insurance | 9237 | 5008 | 24315 | 12352 |
| Interest expense (right-of-use asset) | 12087 | 16221 | 39408 | 51657 |
| Rent expense | 4905 | 1311 | 15655 | 2622 |
| Transfer agent and filing fees | 7693 | 27533 | 20082 | 66097 |
| Travel | 399 | 2467 | 3497 | 3055 |
| Salaries | 52780 | 62764 | 144212 | 134889 |
| Share-based compensation | 107556 | 139498 | 330910 | 585289 |
| Total general and administrative expenses | $470999 | $544054 | $1424242 | $1607115 |

---

13. SALES, MARKETING AND PROMOTIONAL EXPENSES

*The significant components of marketing and promotional expenses are as follows:*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Sales, marketing and promotion | $58238 | $131950 | $200433 | $509670 |
| Office and miscellaneous | 5170 | 7000 | 10523 | 7096 |
| Travel | 7182 | 20604 | 26135 | 31561 |
| Salaries | 96534 | 381589 | 403700 | 1157571 |
| Share-based compensation | 192 | 5743 | (10943) | 30651 |
| Total sales, marketing and promotional expenses | $167316 | $546886 | $629848 | $1736549 |

---

14. INCOME TAXES

Our effective income tax rate was 0.00% for the nine months ended November 30, 2022 was consistent with the rate of 0.00% for the same period of 2021. The effective tax rate for the nine months ended November 30, 2022 was different from the U.S. statutory tax rate of 21% due to increase in valuation allowance in the periods.

15. COMMITMENTS AND CONTINGENCIES

*Legal Contingencies*

From time to time, the Company may be a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of November 30, 2022, there are no litigations pending that could have, individually and in the aggregate, a material adverse effect on the Company's financial position, results of operations or cash flows.

*Accrued Liabilities:*

Accrued expenses consist of the following:

[**Table of Contents**](#TOC)

**LEXAGENE HOLDINGS INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOVEMBER 30, 2022 AND 2021**

**(expressed in US dollars)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **November 30, 2022** | **February 28, 2022** |
| Accrued payroll, compensation and benefits | $80657 | $182367 |
| Accrued professional services | 92982 | 133088 |
| Other accrued expenses | 13532 | 36720 |
| Total accrued expenses and other current liabilities | $187171 | $352175 |

---

16. SUPPLEMENTAL CASH FLOW INFORMATION

---

| | | |
|:---|:---|:---|
|  | **November 30, 2022** | **November 30, 2021** |
| Interest paid | $— | $— |
| Taxes paid |  |  |
| Total | $— | $— |

---

[**Table of Contents**](#TOC)

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Cautionary Note Regarding Forward Looking Statements**

This Quarterly Report on Form 10-Q ("Form 10-Q") contains statements that are, or may be considered to be, "forward-looking statements." Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions. All statements other than statements of historical fact included in this Form 10-Q regarding the prospects of LexaGene Holdings, Inc., ("LexaGene", the "Company" or "we"), the industry or its prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as "plans," "expects" or "does not expect," "is expected," "look forward to," "budget," "scheduled," "estimates," "forecasts," "will continue," "intends," "the intent of," "have the potential," "anticipates," "does not anticipate," "believes," "should," "should not," or variations of such words and phrases that indicate that certain actions, events or results "may," "could," "would," "might," or "will," "be taken," "occur," or "be achieved," or the negative of these terms or variations of them or similar terms. Furthermore, forward-looking statements may be included in various filings that the Company makes with the SEC or press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. (All capitalized and undefined terms used in this section shall have the same meanings hereafter defined in this Quarterly Report on Form 10-Q.)

*The following discussion and analysis of financial condition and results of operations should be read in conjunction with, and is qualified in its entirety by, the unaudited condensed consolidated financial statements and the accompanying notes in this Form 10-Q and the sections entitled "Item 1A. Risk Factors" and "Item 2. Financial Information" in our Annual Report on Form 10 for the year ended February 28, 2022. Except for historical information, the discussion in this section contains forward-looking statements that involve risks and uncertainties, as discussed in the "Cautionary Note Regarding Forward Looking Statements." Future results could differ materially from those discussed below for many reasons, including the risks described in Item 1A—"Risk Factors" in our Annual Report on Form 10 for the year ended February 28, 2022, and in Part II, Item 1A—Risk Factors" of this Form 10-Q.*

***Management's Discussion & Analysis of LexaGene Holdings, Inc.***

For purposes of this discussion, "LexaGene," "we," or the "Company" refers to LexaGene Holdings, Inc. and its wholly-owned subsidiaries: LexaGene, Inc. and Bionomics Diagnostics, Inc. The results herein have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

Amounts are presented in thousands of United States dollars, unless otherwise indicated.

***Business Overview***

LexaGene is a molecular diagnostics company that develops diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

The Company's shares trade on the TSXV under the symbol LXG and on the OTCQB Venture Market in the United States under the symbol LXXGF.

***Transition to US GAAP From IFRS***

During the year ended February 28, 2022, the Company transitioned to US GAAP from IFRS. As a result, the information related to the year ended February 28, 2021 has been recast to conform with US GAAP.

[**Table of Contents**](#TOC)

**Selected Financial Information**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Total revenues | $42912 | $48309 | $117886 | $88934 |
| Cost of revenues | $189928 | $148571 | $592296 | $378188 |
| Selling, marketing and promotional expenses | $167316 | $546886 | $629848 | $1736549 |
| General administrative expenses | $470999 | $544054 | $1424242 | $1607115 |
| Research and development expenses | $887336 | $1506024 | $3357090 | $4709756 |
| Other income (expense) | $(5688) | $5546 | $(5688) | $32000 |
| Net loss and comprehensive loss | $(1686992) | $(2695761) | $(5910991) | $(8158111) |
| Loss per common share | $(0.01) | $(0.02) | $(0.04) | $(0.07) |
| Total assets | $3489764 | $5449980 | $3489764 | $5449980 |
| Long-term liabilities | $561160 | $910287 | $561160 | $910287 |
| Working capital | $640285 | $2980475 | $640285 | $2980475 |

---

**Three Months Ended November 30, 2022 Compared to Three Months Ended November 30, 2021**

***Revenue***

The Company's revenue is derived from the sale of MiQLab Systems and its consumables.

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase**<br>**(Decrease)** |
| Total revenues | $42912 | $48309 | (11)% |

---

Revenues remained consistent from year to year. During the three months ended November 30, 2022, the Company recognized revenue of $42,912 from product sales as compared to $48,309 for revenues during the three months ended November 30, 2021 as the Company sold two units in both of the three-month periods.

***Cost of Revenues***

Cost of goods sold includes the cost of inventory sold and production costs expensed. Direct and indirect production costs include direct labor, processing, testing, packaging, quality assurance, shipping, production management and other related expenses. The primary factors that can impact cost of goods sold on a period-to-period basis include the volume of products sold, the mix of product sold, transportation, and overhead allocations.

The components of cost of goods sold are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase**<br>**(Decrease)** |
| Cost of revenues | $189928 | $148571 | 28% |
| Inventory expensed to cost of goods sold | $44338 | $49668 | (11)% |
| Other production costs | 145590 | 98903 | 47% |
| Total | $189928 | $148571 | 28% |

---

During the period ended November 30, 2022, the Company incurred an expense of $189,928 in relation to the MiQLab System product line as compared to $148,571 for the same period in 2021. This increase of $41,357 is primarily the result of the following items:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Wages and salaries increased to $120,643 during the three months ended November 30, 2022 compared to $79,752 in the same period of 2021. The increase is due to the increase in the number of production staff.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The Company determined that one MiQLab System and its consumables were unrecoverable and expensed those material costs to cost of revenues. The Company made numerous attempts to collect the unit from a customer but was unable to do so.

[**Table of Contents**](#TOC)

***Gross Loss***

The primary factors that can impact gross margins include the volume of products sold, the mix of products sold, transportation costs and changes in inventory costs.

Gross loss is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase**<br>**(Decrease)** |
| Gross loss | $147016 | $100262 | 47% |

---

Gross loss increased by 47% for the three months ended November 30, 2022 compared to 2021 caused by an increase in cost of goods sold and minimal changes in revenue. An increase in cost of goods sold is due to an increase in a number of manufacturing employees and the MiQLab System written off by the Company.

***Selling, General and Administrative Expenses, and Research and Development***

*Total Selling, general, and administrative and research and development expenses are as follows:*

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase**<br>**(Decrease)** |
| Sales and marketing expenses | $167316 | $546886 | (69)% |
| General and administrative expenses | 470999 | 544054 | (13)% |
| Research and development expenses | 887336 | 1506024 | (41)% |
| Total | $1525651 | $2596964 | (41)% |

---

*Sales, marketing and promotional expense*

Comparing the three months ended November 30, 2022 to the same period in 2021, sales, marketing and promotional expenses decreased to $167,316 from $546,866. This decrease of $379,570 in sales, marketing and promotional expenses is primarily from the following items:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Salaries and wages associated with sales, marketing and promotional activities decreased to $96,534 during the three months ended November 30, 2022, as compared to $381,589 for the same period in 2021. This decrease of $285,055 in expense in salaries and wages is directly related to the decrease in headcount year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Marketing, advertising and promotional expenses decreased to $58,238 during the three months ended November 30, 2022, from $131,950 for the same period in 2021. This decrease of $73,712 is related to the Company focusing on specific major conferences during 2022 in addition to reducing the use of outside marketing consultants in order to conserve capital.

*General and administrative expenses*

General and administrative expenses remained relatively consistent during the three months ended November 30, 2022 compared to the same period of 2021. However, there have been changes in the composition of these expenses as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Professional fees expense increased to $189,308 in 2022, as compared to $101,743 for the same period in 2021. This increase during the three months ended November 30, 2022, of $87,565 is directly related to the legal expenses in connection with the convertible debenture, quarterly reviews and SEC filing obligations due to the changes related to the Company ' s filing status.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Transfer agent and filing fees decreased by $19,840 in 2022 as compared to the same period in 2021. This decrease is primarily related to the filing fees incurred during the three months ended November 30, 2021 in relation to the Short Form Base Shelf Prospectus that the Company had filed.

● Costs associated with investor relations decreased to $8,611 in 2022, as compared to $110,776 for the same period in 2021. This decrease of $102,165 in expense for the three months ended November 30, 2022, as compared to same period in 2021, is due to the Company reducing its cash burn by reducing expenses for outside investor relation activities.

[**Table of Contents**](#TOC)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Share-based compensation expense decreased to $107,556 in 2022, as compared to $139,498 in 2021. This decrease of $31,942 in expense is from the decrease in the value of new options and restricted share units granted to employees as compared to the same period in 2021 as well as forfeitures of the previously granted options and RSUs due to employee departures.

*Research and development expenses*

Comparing the three months ended November 30, 2022, to the same period in 2021, research and development expenses decreased to $887,336 from $1,506,024. This decrease in expense of $618,688 in research and development expenses is primarily from the following items:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Salaries and wages decreased to $630,764 for the three months ended November 30, 2022, compared to $886,232 for the three months ended November 30, 2021. This decrease of $255,468 is directly related to the decrease in headcount year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· For the three months ended November 30, 2022, share-based compensation decreased to $30,785 as compared to $83,663 for the same period in 2021. This decrease of $52,878 in expense is from the decrease in the value of new options and restricted share units granted to employees in addition to the forfeiture of unvested stock options and unvested restricted share units previously granted to employees that have left the Company during the three months ended November 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· MiQLab System materials decreased by $266,978 from $327,210 in 2021 to $60,232 for the three months ended November 30, 2022 in comparison to the same period in 2021. Lab administration and supplies decreased from $141,042 to $101,100. These decreases were due to the Company ' s efforts to control costs to reduce the Company ' s cash burn.

***Net Loss and Comprehensive Loss***

For the three months ended November 30, 2022, Net loss decreased by 38% and comprehensive loss decreased by 34% as compared to the same period in 2021. Total net loss and comprehensive loss is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended November 30,** | **Three Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase** <br>**(Decrease)**  |
| Net loss | $1678454 | $2691680 | (38)% |
| Comprehensive loss | $1686992 | $2695761 | (37)% |

---

**Nine Months Ended November 30, 2022 Compared to Nine Months Ended November 30, 2021**

***Revenue***

The Company's revenue is derived from the sale of MiQLab Systems and its consumables.

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase**<br>**(Decrease)** |
| Total revenues | $117886 | $88934 | 33% |

---

The increase of 33% in revenue recognized during the nine months ended November 30, 2022 is largely due to the Company selling five units and consumables during the nine months ended November 30, 2022 compared to four units and consumables in the same period of 2021.

***Cost of Revenues***

Cost of goods sold include the cost of inventory sold and production costs expensed. Direct and indirect production costs include direct labor, processing, testing, packaging, quality assurance, shipping, production management and other related expenses. The primary factors that can impact cost of goods sold on a period-to-period basis include the volume of products sold, the mix of product sold, transportation, and overhead allocations.

[**Table of Contents**](#TOC)

The components of cost of goods sold are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase**<br>**(Decrease)**  |
| Cost of revenues | $592296 | $378188 | 57% |
| Inventory expensed to cost of goods sold | $142149 | $88048 | 61% |
| Other production costs | 450147 | 290140 | 55% |
| Totals | $592296 | $378188 | 57% |

---

During the nine month period ended November 30, 2022, the Company incurred an expense of $592,296 in relation to the MiQLab System product line as compared to $378,188 for the same period in 2021. This increase of $214,108 is primarily the result of the following items:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Costs of revenues increased during the nine months ended November 30, 2020 as compared to the same period in 2021. This increase is directly related to the increase in MiQLab Systems sold as well as the increase in costs related to raw materials caused by inflation as compared to the same period in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Salaries and wages associated with manufacturing units and consumables as well as costs incurred from the installation of units increased to $346,565 during the nine months ended November 30, 2022, as compared to $231,103 for the same period in 2021. This increase of $115,462 in expense in salaries and wages is directly related to the increase in manufacturing headcount as compared to the same period in 2021.

***Gross Loss***

The primary factors that can impact gross margins include the volume of products sold, the mix of products sold, transportation costs and changes in inventory costs.

Gross loss is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase** <br>**(Decrease)**  |
| Gross loss | $474410 | $289254 | 64% |

---

Gross loss increased 64% for the nine months ended November 30, 2022 compared to 2021. This is due to an increase in manufacturing salaries and wages.

***Selling, General and Administrative Expenses, and Research and Development***

*Total Selling, general, and administrative and research and development expenses are as follows:*

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase** <br>**(Decrease)** |
| Sales, marketing and promotional expenses | $629848 | $1736549 | (64)% |
| General and administrative expenses | 1424242 | 1607115 | (11)% |
| Research and development expenses | 3357090 | 4709756 | (29)% |
| Totals | $5411180 | $8053420 | (33)% |

---

[**Table of Contents**](#TOC)

*Sales, marketing and promotional expenses*

Comparing the nine months ended November 30, 2022 to the same period in 2021, sales, marketing and promotional expenses decreased to $629,848 from $1,736,549. This decrease of $1,106,701 in sales, marketing and promotional expenses is primarily from the following items:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Salaries and wages associated with sales, marketing and promotional activities decreased to $403,700 during the nine months ended November 30, 2022, as compared to $1,157,571 for the same period in 2021. This decrease of $753,871 in expense in salaries and wages is directly related to the decrease in headcount year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Marketing, advertising and promotional expenses decreased to $200,433 during the nine months ended November 30, 2022, from $509,670 for the same period in 2021. In the nine-month period ended November 30, 2021, the Company engaged several outside marketing consultants for a marketing campaign and other work, which was not repeated in the same period of 2022.

● Share-based compensation decreased by $41,594 during the period ended November 30, 2022 compared to the same period in 2021 due to the lower value of awards granted in 2022 and forfeitures of awards granted in previous years.

*General and administrative expenses*

Comparing the nine months ended November 30, 2022, to the same period of 2021, general and administrative expenses decreased to $1,424,242 from $1,607,115. This decrease in expense of $182,873 in general and administrative activities are primarily from the following items:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Share-based compensation expense decreased to $330,910 in 2022, as compared to $585,289 in 2021. This decrease of $254,379 in expense is from the decrease in the value of new options and restricted share units granted to employees as compared to the same period in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Costs associated with investor relations decreased to $25,614 in 2022, as compared to $257,040 for the same period in 2021. This decrease of $231,426 in expense for the nine months ended November 30, 2022, as compared to same period in 2021, is due to the Company reducing its cash burn by reducing expenses for outside investor relation activities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Transfer agent and filing fees decreased by $46,015 to $20,082 during the nine months ended November 30, 2022 as compared to the same period in 2021. This decrease is mainly attributed to costs associated with the filing of its Short Form Base Shelf Prospectus in 2021.

● During the nine months ended November 30, 2022, professional fees increased to $591,889 from $258,194 as compared to the same period in 2021. This increase of $333,695 was a result of additional legal, accounting and other professional services required in relation to the Company's filings of its Form 10 and the amendment to Form 10, SEC filing requirements, as well as additional costs incurred in relation to the convertible debenture that the Company entered into during the nine months ended November 30, 2022.

*Research and development expenses*

Comparing the nine months ended November 30, 2022, to the same period in 2021, research and development expenses decreased to $3,357,090 from $4,709,756. This decrease in expense of $1,352,666 in research and development expenses is primarily from the following items:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Salaries and wages decreased to $2,146,302 for the nine months ended November 30, 2022, compared to $2,699,286 for the nine months ended November 30, 2021. This decrease of $552,984 is directly related to the decrease in headcount year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· For the nine months ended November 30, 2022, share-based compensation decreased to $119,738 as compared to $363,337 for the same period in 2021. This decrease of $243,599 in expense is from the decrease in the value of new options and restricted share units granted to employees, as well as the forfeiture of unvested stock options and unvested restricted share units previously granted to employees that have left the Company during the nine months ended November 30, 2022.

[**Table of Contents**](#TOC)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Materials used in research and development decreased to $415,735 during the nine-month period ended November 30, 2022 compared to $999,528 in the same period of 2021. This decrease of $583,793 is related to the Company prioritizing research and development projects related to the MiQLab System product line as compared to materials purchased and optimization required for the FDA EUA-related projects in 2021.

● Lab administration and supplies increased to $428,564 in 2022 as compared to $395,768 for the same period in 2021. This increase of $32,796 was mainly attributed to the increase in costs associated with inflationary increases in chemistries, buffers and other materials used within the Company's labs.

***Net Loss and Comprehensive Loss***

For the nine months ended November 30, 2022, Net loss decreased by 29% and comprehensive loss decreased by 27% as compared to the same period in 2021. Total net loss and comprehensive loss is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase** <br>**(Decrease)** |
| Net loss | $5891278 | $8310674 | (29)% |
| Comprehensive loss | $5910991 | $8158111 | (27)% |

---

**Liquidity, Capital Resources and Going Concern**

The Company's working capital as of November 30, 2022 was $640,285 including cash of $464,131 compared to a working capital of $5,676,454 including cash of $4,722,710 as of February 28, 2022.

The Company's business currently does not generate positive cash flows from operations. As of November 30, 2022, the Company had an accumulated deficit of $50,339,236 since inception. Management's plans to meet the Company's current and future obligations are to raise capital in equity and private debt markets, private placements, rely on the financial support of its shareholders and related parties as well as to further expand commercial sales of the MiQLab System. There can be no assurance that the Company will be successful in raising that additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditures.

The Company believes that its cash of $464,131 as of November 30, 2022 will not be sufficient to fund its current operating plan at least one year from issuance of these condensed financial statements unless additional funds are raised. Certain elements of our operating plan cannot be considered probable.

These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of issuance of these condensed consolidated financial statements. See Note 1 of the Condensed Consolidated Financial Statements.

The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company's products, development and market acceptance of the Company's product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital. The Company's ability to fund operating expenses and capital expenditures will depend on its future operating performance, the ability to further develop its genetic analyzer, the MiQLab System, which will be affected by general economic conditions, financial, regulatory, and other factors beyond the Company's control (See *"Risk Factors"*).

**Cash Flows**

The Company's working capital as of November 30, 2022, was $640,285 including cash of $464,131 compared to a working capital of $2,980,475 including cash of $1,715,440 as of November 30, 2021.

[**Table of Contents**](#TOC)

The Company's business currently does not generate positive cash flows from operations. On November 30, 2022, the Company had an accumulated deficit of $50,339,236 since inception. The Company is reliant on equity financings to provide the necessary cash to continue the commercialization of the MiQLab System described in the Summary of Operations, and generating cash flow from operations in the future. These factors form a material uncertainty, which may raise significant doubt about the Company's ability to continue as a going concern.

***Cash from Operating Activities***

Net cash used in operating activities for the nine months ended November 30, 2022 and for the same period in 2021 were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase** <br>**(Decrease)**  |
| Cash used in operating activities | $5063871 | $7809568 | (35)% |

---

The decrease of $2,745,697 in the amount of cash used was primarily due to the Company significantly reducing its expenses during the period, purchasing less inventory in 2022 and the timing of repayment of accounts payable.

***Cash from Investing Activities***

Net cash used in investing activities for the nine months ended November 30, 2022 and for the same period in 2021 were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase**<br>**(Decrease)** |
| Cash used in investing activities | $— | $(17860) | (100)% |

---

During the period ended November 30, 2021, the Company purchased $17,860 of property and equipment compared to none purchased during the same period of 2022. As a result, no cash was used in investing activities of the nine months ended November 30, 2022, compared to $17,860 used in the same period of 2021.

***Cash Provided by (Used in) Financing Activities***

Net cash provided by (used in) financing activities for the nine months ended November 30, 2022 and for the same period in 2021 were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended November 30,** | **Nine Months Ended November 30,** | |
|  | **2022** | **2021** | **% Increase**<br>**(Decrease)** |
| Cash provided by (used in) financing activities | $809491 | $(239117) | 439% |

---

Cash provided by financing activities during the period ended November 30, 2022 increased by 467% or $1,048,608 compared to the same period of 2021, due to cash obtained through a convertible note in the amount of $900,000 and $263,295 generated through warrant exercises by warrant holders.

**Critical Accounting Policies and Estimates**

Note 2 to the Condensed Consolidated Financial Statements of the Company for 2022 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. During the period ended November 30, 2022, the Company early adopted ASU 2020-06. There have been no other significant changes in the company's critical accounting policies during the nine months ended November 30, 2022.

**Recent Accounting Pronouncements**

Note 2 to the Condensed Consolidated Financial Statements describes recent accounting pronouncements under the header *Recent Accounting Standards*.

[**Table of Contents**](#TOC)

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

The information under this item is not required to be provided by smaller reporting companies.

**Item 4. Controls and Procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of November 30, 2022, our disclosure controls and procedures were effective to ensure the timely disclosure of required information in our SEC filings.

**Changes in Internal Control Over Financial Reporting**

There were no changes in the Company's internal control over financial reporting during the quarter ending November 30, 2022 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**PART II – OTHER INFORMATION**

**Item 1. Legal Proceedings**

From time to time, the Company may be involved in various regulatory issues, claims and lawsuits arising in the ordinary course of business, none of which, in the opinion of management, is expected to have a material adverse effect on the Company's results of operations or financial condition.

At present, the Company is not a party to any material pending legal proceedings, other than ordinary routine litigation incidental to the business. Nor is the Company or its property the subject of any legal proceedings, known or contemplated, that involve a claim for damages exclusive of interest and costs that meet or exceed 10% of its current assets.

**Item 1A. Risk Factors**

Our Annual Report on Form 10 for the year ended February 28, 2022 includes a detailed discussion of our risk factors under the heading "Part I, Item 1A—Risk Factors." Except as set forth below, there have been no material changes from such risk factors during the quarter ended November 30, 2022. You should consider carefully the risk factors set forth in this Form 10-Q and discussed in our Annual Report on Form 10 for the year ended February 28, 2022 and all other information contained in or incorporated by reference in this Form 10-Q before making an investment decision. If any of the risks discussed herein or in the Annual Report on Form 10 for the year ended February 28, 2022 actually occur, they may materially harm our business, financial condition, operating results, cash flows or growth prospects. As a result, the market price of our common shares could decline, and you could lose all or part of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial may also materially harm our business, financial condition, operating results, cash flows or growth prospects and could result in a complete loss of your investment.

***Inflation may adversely affect our business, results of operations and financial condition.***

Our business is impacted by inflation, such as current inflation related to global supply chain disruptions. Recent inflationary pressures have increased the cost of energy and raw materials and may adversely affect consumer spending, economic growth and operations. If we are unable to pass any increases in their costs along to their customers, it could adversely affect our operating results and our ability to raise funding.

***Global economic and geopolitical conditions could adversely affect our operations.***

In recent years, we have been faced with very challenging global economic conditions. The COVID-19 pandemic is currently causing disruptions to global economic conditions. Russia's invasion of Ukraine and sanctions against Russia also are causing disruptions to global economic conditions. It is unknown how long such disruptions will continue and whether such disruptions will become more severe. A deterioration in the global economic environment may result in a decrease in demand for our products, increased competition,

[**Table of Contents**](#TOC)

downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may, and currently is, also adversely affecting our suppliers, which could continue to result in interruptions in the supply of the components and raw materials necessary for our products and raw material cost increases.

***Our current and future debt and related covenants may restrict our future operations.***

Our existing convertible note and agreements we may enter in the future, contain or may contain covenants imposing restrictions on our business. These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. Existing covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An event of default under our convertible note agreement not remediated after 5 days will result in an eventual acceleration of the note and accrual of interest at the default rate of 16%.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

**Item 6. Exhibits**

Documents filed as part of this report:

---

| | |
|:---|:---|
| **ExhibitNumber** | **Description of Document** |
| 31.1 | [Chief Executive Officer Section 302 Certification](lxxgf-20221130xex31d1.htm) |
| 31.2 | [Chief Financial Officer Section 302 Certification](lxxgf-20221130xex31d2.htm) |
| 32.1 | [Chief Executive Officer Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](lxxgf-20221130xex32d1.htm) |
| 32.2 | [Chief Financial Officer Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](lxxgf-20221130xex32d2.htm) |
| 101 | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2022, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags. |
| 104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2022, formatted in Inline XBRL (included within Exhibit 101) |

---

[**Table of Contents**](#TOC)

[**Table of Contents**](#TOC)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **LEXAGENE HOLDINGS INC.** | **LEXAGENE HOLDINGS INC.** |
|  | /s/ Dr. John Regan | /s/ Dr. John Regan |
|  | By: | Dr. John Regan |
| Date: January 17, 2023 | Title:  | Chief Executive Officer |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Dr. John Regan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of LexaGene Holdings, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant [ *omitted pursuant to Exchange Act Rule 13a-14(a)* ] and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) [ *omitted pursuant to Exchange Act Rule 13a-14(a)* ];

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: January 17, 2023

---

| | |
|:---|:---|
|  | /s/ Dr. John Regan |
| Dr. John Regan | Dr. John Regan |
| *Chief Executive Officer* | *Chief Executive Officer* |
| *(Principal Executive Officer)* | *(Principal Executive Officer)* |

---

------

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jeffrey Mitchell, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of LexaGene Holdings, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant [ *omitted pursuant to Exchange Act Rule 13a-14(a)* ] and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) [ *omitted pursuant to Exchange Act Rule 13a-14(a)* ];

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: January 17, 2023

---

| | |
|:---|:---|
|  | /s/ Jeffrey Mitchell |
| Jeffrey Mitchell | Jeffrey Mitchell |
| *Chief Financial Officer* | *Chief Financial Officer* |
| *(Principal Financial and Accounting Officer)* | *(Principal Financial and Accounting Officer)* |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**Certification of Periodic Financial Report**

**Pursuant to 18 U.S.C. Section 1350**

**as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of LexaGene Holdings, Inc. (the "Company") on Form 10-Q for the quarterly period ended November 30, 2022, as filed with the Securities and Exchange Commission (the "Report"), I, Dr. John Regan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Date: January 17, 2023

---

| | |
|:---|:---|
|  | /s/ Dr. John Regan |
| Dr. John Regan | Dr. John Regan |
| *Chief Executive Officer* | *Chief Executive Officer* |
| *(Principal Executive Officer)* | *(Principal Executive Officer)* |

---

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to LexaGene Holdings Inc. and will be retained by LexaGene Holdings Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

------

## Exhibit 32.2

**Exhibit 32.2**

**Certification of Periodic Financial Report**

**Pursuant to 18 U.S.C. Section 1350**

**as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of LexaGene Holdings, Inc. (the "Company") on Form 10-Q for the quarterly period ended November 30, 2022, as filed with the Securities and Exchange Commission (the "Report"), I, Jeffrey Mitchell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Date: January 17, 2023

---

| | |
|:---|:---|
|  | /s/ Jeffrey Mitchell |
| Jeffrey Mitchell | Jeffrey Mitchell |
| *Chief Financial Officer* | *Chief Financial Officer* |
| *(Principal Financial and Accounting Officer)* | *(Principal Financial and Accounting Officer)* |

---

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to LexaGene Holdings Inc. and will be retained by LexaGene Holdings Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

------